ACG CXA EXAM 300 ACTUAL QUESTIONS AND
CORRECT ANSWERS WITH RATIONALE
LATEST UPDATE ALREADY GRADED A+
ASSURED PASS
Section 1: Scientific Concepts and Research Design (Questions
1–40)
1. What is the primary purpose of a clinical trial protocol?
A. To market the investigational product
B. To describe the objectives, design, methodology, and organization of a trial
C. To recruit participants
D. To calculate the budget
Correct Answer: B
Rationale: The protocol is the document that describes the objective(s), design,
methodology, statistical considerations, and organization of a trial. It ensures the
trial is conducted consistently and ethically.
2. Which phase of clinical trials primarily assesses safety and dosage?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A
Rationale: Phase I trials are the first step in testing a new treatment in humans.
They primarily assess safety, determine a safe dosage range, and identify side
effects.
3. Which phase of clinical trials primarily assesses efficacy and side effects?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
,Correct Answer: B
Rationale: Phase II trials test the treatment on a larger group of people to determine
if it works in people who have the target disease and to further evaluate its safety.
4. Which phase of clinical trials compares the new treatment to standard
treatments?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: C
Rationale: Phase III trials compare the new treatment to the current standard
treatment in a large group of participants to confirm its effectiveness and monitor
side effects.
5. What is the purpose of a Phase IV clinical trial?
A. To assess safety and dosage
B. To assess efficacy
C. To compare to standard treatment
D. To monitor long-term safety after marketing approval
Correct Answer: D
Rationale: Phase IV trials, also known as post-marketing studies, are conducted
after a treatment has been approved and is on the market to gather additional
information about its long-term safety and effectiveness.
6. What is an Investigational Brochure (IB)?
A. A document that summarizes the clinical and nonclinical data on an
investigational product
B. A document that describes the study protocol
C. A document that provides informed consent information
D. A document that reports adverse events
Correct Answer: A
Rationale: The IB is a compilation of the clinical and nonclinical data on the
investigational product that is relevant to the study of the product in human
subjects.
,7. What is a primary endpoint in a clinical trial?
A. A secondary measure of interest
B. The main measure of interest that the trial is designed to evaluate
C. A safety measure
D. A demographic measure
Correct Answer: B
Rationale: The primary endpoint is the main result that is measured at the end of a
trial to see if the treatment worked. It is the most important measure of interest.
8. What is a secondary endpoint in a clinical trial?
A. A measure that is not as important as the primary endpoint
B. The main measure of interest
C. A safety measure
D. A demographic measure
Correct Answer: A
Rationale: Secondary endpoints are additional measures of interest that are not as
important as the primary endpoint but provide supporting information about the
treatment's effects.
9. What is a surrogate endpoint?
A. A direct measure of clinical benefit
B. A laboratory measurement or physical sign used as a substitute for a clinically
meaningful endpoint
C. A secondary endpoint
D. A safety endpoint
Correct Answer: B
Rationale: A surrogate endpoint is a biomarker or other measure that is used as a
substitute for a clinically meaningful endpoint, such as survival or symptom
improvement, because it can be measured earlier or more easily.
10. What is a composite endpoint?
A. A single endpoint
B. A combination of multiple endpoints into a single measure
C. A safety endpoint
D. A demographic endpoint
Correct Answer: B
, Rationale: A composite endpoint combines multiple endpoints into a single
measure, often used to increase statistical power by capturing more events.
11. What is randomization in clinical trials?
A. The process of assigning participants to treatment groups by chance
B. The process of selecting participants for a trial
C. The process of measuring outcomes
D. The process of analyzing data
Correct Answer: A
Rationale: Randomization is the process of assigning trial participants to treatment
or control groups using an element of chance to reduce bias and ensure
comparability between groups.
12. What is blinding in clinical trials?
A. The process of keeping one or more parties unaware of the treatment
assignment
B. The process of assigning participants to treatment groups
C. The process of measuring outcomes
D. The process of analyzing data
Correct Answer: A
Rationale: Blinding (or masking) is a procedure in which one or more parties to the
trial are kept unaware of the treatment assignments to reduce bias.
13. What is a double-blind study?
A. A study in which only the participant is unaware of the treatment
B. A study in which only the investigator is unaware of the treatment
C. A study in which neither the participant nor the investigator knows the
treatment assignment
D. A study in which everyone knows the treatment assignment
Correct Answer: C
Rationale: In a double-blind study, neither the participants nor the investigators
(and often the outcome assessors) know which treatment participants are receiving,
which minimizes bias.
14. What is a single-blind study?
A. A study in which neither the participant nor the investigator knows the
treatment
CORRECT ANSWERS WITH RATIONALE
LATEST UPDATE ALREADY GRADED A+
ASSURED PASS
Section 1: Scientific Concepts and Research Design (Questions
1–40)
1. What is the primary purpose of a clinical trial protocol?
A. To market the investigational product
B. To describe the objectives, design, methodology, and organization of a trial
C. To recruit participants
D. To calculate the budget
Correct Answer: B
Rationale: The protocol is the document that describes the objective(s), design,
methodology, statistical considerations, and organization of a trial. It ensures the
trial is conducted consistently and ethically.
2. Which phase of clinical trials primarily assesses safety and dosage?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A
Rationale: Phase I trials are the first step in testing a new treatment in humans.
They primarily assess safety, determine a safe dosage range, and identify side
effects.
3. Which phase of clinical trials primarily assesses efficacy and side effects?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
,Correct Answer: B
Rationale: Phase II trials test the treatment on a larger group of people to determine
if it works in people who have the target disease and to further evaluate its safety.
4. Which phase of clinical trials compares the new treatment to standard
treatments?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: C
Rationale: Phase III trials compare the new treatment to the current standard
treatment in a large group of participants to confirm its effectiveness and monitor
side effects.
5. What is the purpose of a Phase IV clinical trial?
A. To assess safety and dosage
B. To assess efficacy
C. To compare to standard treatment
D. To monitor long-term safety after marketing approval
Correct Answer: D
Rationale: Phase IV trials, also known as post-marketing studies, are conducted
after a treatment has been approved and is on the market to gather additional
information about its long-term safety and effectiveness.
6. What is an Investigational Brochure (IB)?
A. A document that summarizes the clinical and nonclinical data on an
investigational product
B. A document that describes the study protocol
C. A document that provides informed consent information
D. A document that reports adverse events
Correct Answer: A
Rationale: The IB is a compilation of the clinical and nonclinical data on the
investigational product that is relevant to the study of the product in human
subjects.
,7. What is a primary endpoint in a clinical trial?
A. A secondary measure of interest
B. The main measure of interest that the trial is designed to evaluate
C. A safety measure
D. A demographic measure
Correct Answer: B
Rationale: The primary endpoint is the main result that is measured at the end of a
trial to see if the treatment worked. It is the most important measure of interest.
8. What is a secondary endpoint in a clinical trial?
A. A measure that is not as important as the primary endpoint
B. The main measure of interest
C. A safety measure
D. A demographic measure
Correct Answer: A
Rationale: Secondary endpoints are additional measures of interest that are not as
important as the primary endpoint but provide supporting information about the
treatment's effects.
9. What is a surrogate endpoint?
A. A direct measure of clinical benefit
B. A laboratory measurement or physical sign used as a substitute for a clinically
meaningful endpoint
C. A secondary endpoint
D. A safety endpoint
Correct Answer: B
Rationale: A surrogate endpoint is a biomarker or other measure that is used as a
substitute for a clinically meaningful endpoint, such as survival or symptom
improvement, because it can be measured earlier or more easily.
10. What is a composite endpoint?
A. A single endpoint
B. A combination of multiple endpoints into a single measure
C. A safety endpoint
D. A demographic endpoint
Correct Answer: B
, Rationale: A composite endpoint combines multiple endpoints into a single
measure, often used to increase statistical power by capturing more events.
11. What is randomization in clinical trials?
A. The process of assigning participants to treatment groups by chance
B. The process of selecting participants for a trial
C. The process of measuring outcomes
D. The process of analyzing data
Correct Answer: A
Rationale: Randomization is the process of assigning trial participants to treatment
or control groups using an element of chance to reduce bias and ensure
comparability between groups.
12. What is blinding in clinical trials?
A. The process of keeping one or more parties unaware of the treatment
assignment
B. The process of assigning participants to treatment groups
C. The process of measuring outcomes
D. The process of analyzing data
Correct Answer: A
Rationale: Blinding (or masking) is a procedure in which one or more parties to the
trial are kept unaware of the treatment assignments to reduce bias.
13. What is a double-blind study?
A. A study in which only the participant is unaware of the treatment
B. A study in which only the investigator is unaware of the treatment
C. A study in which neither the participant nor the investigator knows the
treatment assignment
D. A study in which everyone knows the treatment assignment
Correct Answer: C
Rationale: In a double-blind study, neither the participants nor the investigators
(and often the outcome assessors) know which treatment participants are receiving,
which minimizes bias.
14. What is a single-blind study?
A. A study in which neither the participant nor the investigator knows the
treatment
